A recent publication by Lancet HIV found a link between the criminalization of drugs and the spread of HIV. Read More »

Omnicell Inc, announced May 1 that they would be allowing patients of AcuDose-Rx Automated Dispensing Cabinets the ability to upgrade to the more specialty XT Series while using their current software. Read More »

Aytu BioScience Inc. has two new posters that exhibit the use of the MiOXSYS System, a tool developed by the company for determining oxidative stress in human semen. Read More »

60 Degrees Pharmaceuticals' study findings on tafenoquine have been published in Travel Medicine and Infectious Disease. Read More »

Sandoz AG, part of Novatis, has made an agreement with DURECT Corp. for the marketing of POSIMIR, an analgesic being developed by DURECT. Read More »

GE Healthcare is working alongside of Check-Cap on the development and validation of a cancer-screening process. Read More »

Portola Pharmaceuticals Inc.'s clinical results from a study will be presented during the International Conference on Malignant Lymphoma. Read More »

The American Society of Hospital Pharmacists (ASHP) recently announced that a new AHFS Drug Information (AHFS DI) has been released. Read More »

Envisia Therapeutics has released an interim analysis on the second cohort of its ENV515 (travoprost XR) Phase 2 trial, which involves patients with glaucoma. Read More »

Amgen recently shared positive results for its Fourier Trial, which is evaluating whether Repatha reduces the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease. Read More »

A patent application has been filed for a new cannabinoid-based topical therapy that will treat glaucoma, the second-leading cause of blindness. Read More »

Eight real-world analyses regarding Entyvio (vedolizumab) for treating adults with moderate to severe ulcerative colitis and Crohn's disease were presented at the 2017 Digestive Disease Week annual scientific meeting. Read More »

Genentech's Phase III IMvigor211 clinical trial did not meet its primary endpoint of overall survival. Read More »

Teva Pharmaceutical Industries Ltd. will make a generic version of Vytorin (ezetimibe and simvastatin) available in America. Read More »

Imprimis Pharmaceutical Inc. launch its new Simple drops glaucoma drops at the American Society of Cataract and Refractive Surgery 2017 meeting at the Los Angeles Convention Center this month. Read More »

Novo Nordisk announced this month a new combo therapy for the treatment of diabetes. Read More »

Teva Pharmaceutical Industries Ltd.'s results from a Phase II/III study ARM-TD (Aim to Reduce Movement in Tardive Dyskinesia) have been published in Neurology, the American Academy of Neurology's medical journal. Read More »

A major pharmacy benefit manager has announced a program to provide discounted drugs to uninsured Americans. Read More »

Celgene Corporation recently announced that the primary endpoint has been met for its Phase III Sunbeam trial, which evaluated the efficacy and safety of ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis (RMS). Read More »

Kaiser Permanente has published research in JAMA Pediatrics that showcases the development of a neonatal sepsis risk calculator that has safely reduced antibiotic use by nearly 50 percent in newborns. Read More »